Queensland Immunology Research Centre (QIRC) will be welcoming Dr Fred Ramsdell, 2025 Nobel Laureate in Physiology or Medicine, internationally recognised immunologist and biotechnology leader, for a special seminar at the Translational Research Institute.

Join us for this opportunity to hear from one of the world's leading immunologists as he presents A New Therapeutic Approach to Autoimmunity.

Event Details

Date: Friday, 14 August 2026
Location: Translational Research Institute (TRI)

Program

12:15pm – Networking Lunch (TRI Atrium)

Begin the afternoon by connecting with colleagues from across Brisbane's immunology community over a light lunch before the seminar.

1:00pm – 2:00pm – Seminar: A New Therapeutic Approach to Autoimmunity (TRI Auditorium)

Registration

Attendance is free; however, registration is essential for catering purposes.

Registrations close Tuesday, 11 August 2026.

About Dr Fred Ramsdell

Fred Ramsdell, Ph.D., is a veteran biotechnology leader in immunology with over three decades of experience. Fred is a founder of Sonoma Biotherapeutics and until recently served as Chief Scientific Officer. Immediately prior to Sonoma, Fred was the CSO at the Parker Institute for Cancer Immunotherapy (PICI) where he helped build and advance multiple research programs from the inception of the Institute. He earned his BS degree from the University of California, San Diego and his doctoral degree in microbiology and immunology from the University of California, Los Angeles. He then completed a fellowship at the NIH and subsequently joined Immunex. He later joined Darwin Molecular (acquired by Celltech, Inc) where his team’s efforts included the discovery of FOXP3, the key factor for regulatory T cell development and activity. The discovery was awarded the 2017 Crafoord Prize and the 2025 Nobel Prize in Physiology or Medicine. Fred has also held leadership positions at ZymoGenetics and Novo Nordisk and currently sits on various Scientific Advisory Boards and Grant Review agencies.